摘要
冠心病是全球范围内导致心血管事件和死亡的主要原因之一，血脂异常是其重要危险因素。本研究旨在探讨阿托伐他汀在冠心病患者调脂治疗中的临床效果及其安全性。研究选取200例确诊为冠心病且伴有血脂异常的患者，随机分为实验组和对照组，各100例。实验组接受阿托伐他汀常规剂量治疗，对照组仅采用基础生活方式干预，疗程持续12个月。通过定期检测血脂水平、炎症指标及心血管事件发生率，评估治疗效果。结果显示，实验组患者的低密度脂蛋白胆固醇（LDL-C）水平显著降低，高密度脂蛋白胆固醇（HDL-C）水平有所升高，同时C反应蛋白水平明显下降，心血管事件发生率较对照组显著减少。此外，阿托伐他汀治疗期间未观察到严重不良反应，表明其具有良好的耐受性。本研究创新性地结合血脂改善与炎症控制指标，进一步验证了阿托伐他汀在冠心病二级预防中的重要作用，为临床调脂治疗提供了更为精准的参考依据。关键词：冠心病；阿托伐他汀；血脂异常；低密度脂蛋白胆固醇；炎症指标
Observation on the Application of Atorvastatin in Lipid-Regulating Therapy for Coronary Heart Disease Patients
Abstract
Coronary heart disease (CHD) is one of the leading causes of cardiovascular events and mortality worldwide, with dyslipidemia being a major risk factor. This study aimed to investigate the clinical efficacy and safety of atorvastatin in lipid-lowering therapy for patients with CHD. A total of 200 patients diagnosed with CHD and accompanying dyslipidemia were randomly divided into an experimental group and a control group, each consisting of 100 patients. The experimental group received routine-dose atorvastatin treatment, while the control group only underwent basic lifestyle interventions. The treatment lasted for 12 months. Treatment outcomes were evaluated through regular monitoring of lipid profiles, inflammatory markers, and the incidence of cardiovascular events. The results demonstrated that low-density lipoprotein cholesterol (LDL-C) levels in the experimental group significantly decreased, high-density lipoprotein cholesterol (HDL-C) levels increased to some extent, C-reactive protein levels markedly declined, and the incidence of cardiovascular events was significantly lower compared to the control group. Furthermore, no severe adverse reactions were observed during atorvastatin treatment, indicating its favorable tolerability. This study innovatively integrated lipid improvement with inflammatory control indicators, further validating the critical role of atorvastatin in secondary prevention of CHD and providing more precise reference evidence for clinical lipid-regulating therapy.
Keywords: Coronary Heart Disease; Atorvastatin; Dyslipidemia; Low-Density Lipoprotein Cholesterol; Inflammatory Markers
目录
摘要 I
Abstract II
引言 1
1 阿托伐他汀调脂机制研究 1
1.1 调脂药物作用原理 1
1.2 阿托伐他汀代谢路径 2
1.3 临床调脂机制分析 2
2 冠心病患者血脂特征分析 3
2.1 冠心病与血脂关系 3
2.2 患者血脂水平评估 3
2.3 血脂异常风险因素 4
3 阿托伐他汀治疗效果观察 4
3.1 治疗方案设计与实施 4
3.2 血脂指标变化监测 5
3.3 疗效评价标准分析 5
4 安全性与依从性探讨 5
4.1 不良反应发生情况 5
4.2 患者依从性影响因素 6
4.3 安全性优化策略研究 6
结论 7
参考文献 8
致谢 9
